"Nuclear Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteins found in the nucleus of a cell. Do not confuse with NUCLEOPROTEINS which are proteins conjugated with nucleic acids, that are not necessarily present in the nucleus.
| Descriptor ID |
D009687
|
| MeSH Number(s) |
D12.776.660
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Nuclear Proteins".
Below are MeSH descriptors whose meaning is more specific than "Nuclear Proteins".
This graph shows the total number of publications written about "Nuclear Proteins" by people in this website by year, and whether "Nuclear Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 14 | 3 | 17 |
| 1997 | 21 | 11 | 32 |
| 1998 | 17 | 9 | 26 |
| 1999 | 16 | 6 | 22 |
| 2000 | 22 | 9 | 31 |
| 2001 | 20 | 10 | 30 |
| 2002 | 20 | 8 | 28 |
| 2003 | 18 | 16 | 34 |
| 2004 | 22 | 19 | 41 |
| 2005 | 15 | 20 | 35 |
| 2006 | 14 | 6 | 20 |
| 2007 | 19 | 11 | 30 |
| 2008 | 16 | 13 | 29 |
| 2009 | 17 | 13 | 30 |
| 2010 | 15 | 3 | 18 |
| 2011 | 19 | 10 | 29 |
| 2012 | 14 | 10 | 24 |
| 2013 | 23 | 11 | 34 |
| 2014 | 12 | 18 | 30 |
| 2015 | 21 | 8 | 29 |
| 2016 | 19 | 15 | 34 |
| 2017 | 23 | 14 | 37 |
| 2018 | 18 | 14 | 32 |
| 2019 | 8 | 10 | 18 |
| 2020 | 12 | 12 | 24 |
| 2021 | 11 | 4 | 15 |
| 2022 | 4 | 9 | 13 |
| 2023 | 3 | 13 | 16 |
| 2024 | 4 | 8 | 12 |
| 2025 | 6 | 4 | 10 |
| 2026 | 4 | 2 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Nuclear Proteins" by people in Profiles.
-
Development of a structurally distinct TopBP1 inhibitor that enhances PARP blockade and reverses osimertinib resistance. Sci Adv. 2026 Aug 07; 12(32):eaeg1996.
-
Overcoming menin inhibitor resistance in AML cells with combinations including BET proteins and a dual BRG1/BRM inhibitor. Blood. 2026 Jun 04; 147(23):2809-2820.
-
Generation and Characterization of Twist1 Acetyl-Mimic and Acetyl-Deficient Mouse Models. Genesis. 2026 06; 64(3):e70062.
-
Synthesis, structure-activity relationships, antitumor activities and mechanistic studies of ENL-degrading compounds. Eur J Med Chem. 2026 Oct 15; 316:118989.
-
Frequent synaptophysin expression in SMARCA4-deficient undifferentiated carcinoma of the oesophagus: a diagnostic pitfall with therapeutic implications. J Clin Pathol. 2026 Mar 19; 79(4):229-237.
-
Paediatric Therapeutic Development Workshop on rhabdoid tumours. Br J Cancer. 2026 Jun; 134(11):1510-1528.
-
Aberrant nuclear pore complex degradation contributes to neurodegeneration in VCP disease. Neuron. 2026 Mar 04; 114(5):850-867.e8.
-
Mutant p53 variants differentially impact replication initiation and activate cGAS-STING to affect immune checkpoint inhibition. Commun Biol. 2025 Nov 05; 8(1):1522.
-
Disparate leukemia mutations converge on nuclear phase-separated condensates. Cell. 2025 Dec 11; 188(25):7118-7136.e21.
-
The ClinGen Severe Combined Immunodeficiency Disease Variant Curation Expert Panel: Specifications for classification of variants in ADA, DCLRE1C, IL2RG, IL7R, JAK3, RAG1, and RAG2. Genet Med. 2026 Jan; 28(1):101613.